Author

A. Yoshimura

Institutions: Kyoto first Red Cross hospital, Japanese Red Cross Society Kyoto Daini Hospital

Observed institutions: Kyoto first Red Cross hospital, Japanese Red Cross Society Kyoto Daini Hospital

ORCID: 0000-0002-3753-2110

Observed ORCID: 0000-0002-3753-2110

OpenAlex ID: A5042944181

Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer

2026 · Y. Katayama, A. Fukuda, et al. · ESMO Open · 5

1013P Impact of chemoimmunotherapy approval on post-EGFR-TKI treatment outcomes in EGFR-mutant NSCLC: Insights from a real-world Japanese cohort

2025 · T. Yamada, K. Morimoto, et al. · Annals of Oncology

1011P Impact of initial biomarker testing strategy on clinical outcomes in advanced non-squamous NSCLC: A multicenter retrospective cohort study in Japan

2025 · I. Masaki, T. Yamada, et al. · Annals of Oncology

1869P Real-world benefit of chemoimmunotherapy in patients with low PD-L1 NSCLC: Impact of clinical trial eligibility status

2025 · I. Masaki, T. Hata, et al. · Annals of Oncology

Works count: 4

Citation count: 5

H-index: 1

I10-index: